Low NO bioavailability in CCl₄ cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: A comparison of two portal hypertensive rat models with healthy controls

Marc Van de Casteele*1, Jos F van Pelt1, Frederik Nevens1, Johan Fevery1 and Jürg Reichen2

Address: 1Department of Hepatology, Catholic University of Leuven, Herestraat 49, B-3000 Leuven, B-3000 Leuven, Belgium and 2Institute of Clinical Pharmacology, University of Berne, Murtenstrasse 35, CH-3010 Berne, Switzerland

Email: Marc Van de Casteele* - marc.vandecasteele@uz.kuleuven.ac.be; Jos F van Pelt - jos.vanpelt@med.kuleuven.ac.be; Frederik Nevens - frederik.nevens@uz.kuleuven.ac.be; Johan Fevery - johan.fevery@uz.kuleuven.ac.be; Jürg Reichen - juerg.reichen@ikp.unibe.ch

* Corresponding author

Abstract

Background: In cirrhotic livers, the balance of vasoactive substances is in favour of vasoconstrictors with relatively insufficient nitric oxide. Endothelial dysfunction has been documented in cirrhotic rat livers leading to a lower activity of endothelial nitric oxide synthase but this might not be sufficient to explain the low nitric oxide presence. We compared the amount of all nitric oxide synthase isoforms and other factors that influence nitric oxide bioavailability in livers of two portal hypertensive rat models: prehepatic portal hypertension and carbon tetrachloride induced cirrhosis, in comparison with healthy controls.

Results: Endothelial nitric oxide synthase was the solely detected isoform by Western blotting in all livers. In cirrhotic livers, the amount of endothelial nitric oxide synthase protein was lower than in healthy controls, although an overlap existed. Levels of caveolin-1 messenger RNA were within the normal range but endothelin-1 messenger RNA levels were significantly higher in cirrhotic livers (p < 0.05). A markedly lower superoxide dismutase activity was observed in cirrhotic livers as compared to healthy controls (p < 0.05).

Conclusions: In contrast to prehepatic portal hypertension, cirrhotic livers had decreased endothelial nitric oxide synthase protein and enhanced endothelin-1 messenger RNA amount. We hypothesise that a vasodilator/vasoconstricter imbalance may be further aggravated by the reduced activity of superoxide dismutase. Decreased activity allows enhanced superoxide action, which may lead to breakdown of nitric oxide in liver sinusoids.

Background

The balance of vasoactive substances in cirrhotic livers is in favour of vasoconstrictors [1–3]. This contrasts with splanchnic and systemic vasodilatation characteristically
seen in this condition [1,2]. Nitric oxide (NO), prostacyclin and carbon monoxide are known as intrahepatic vasodilating substances, whereas endothelin–1, superoxide (O$_2^-$), angiotensin-II, epinephrine and others act as vasoconstricting agents [1–6]. NO is produced by 3 different nitric oxide synthase (NOS) isoforms: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS) [1]. The latter is in a normal liver clearly present in endothelial cells of portal venules, portal arterioles and central venules, as well as in sinusoidal endothelial cells [7,8]. Other liver cell types such as hepatic stellate [9,10], Kupffer cells [9] or hepatocytes [7,9] do not express eNOS. A diminished hepatic activity of eNOS by about 30–50% was documented in carbon tetrachloride (CCl$_4$) induced cirrhosis [7–9,11], in biliary fibrosis of the rat [9,12] and in advanced human cirrhosis [13]. This led to the concept that decreased hepatic NO bioavailability in case of cirrhosis is due to decreased NO synthesis [7,9,11–13]. The contribution of nNOS and iNOS to portal hypertension is not well studied [3]. In the present study, we wanted to know which NOS isoform was the most abundant in rat livers in normal conditions and in two different models of portal hypertension: prehepatic portal hypertension and CCl$_4$ cirrhosis.

Furthermore, the reason of decreased hepatic NO bioavailability in case of cirrhosis is not yet elucidated. One of the inhibitors of eNOS catalytic activity is caveolin-1 [14], whereas endothelin-1 counteracts the vasodilating effect of NO via endothelin-A receptors [1,3,5]. Finally, NO can be scavenged by O$_2^-$ [1,15] and superoxide dismutase (SOD) catalyses O$_2^-$ breakdown [15,16]. Because SOD and NO compete for O$_2^-$, SOD can be regarded as a "NO sparing" enzyme [17,18] (Fig. 1). This finding is relevant not only in the context of oxidative stress in cirrhotic livers. It also concerns eNOS itself, because eNOS can synthesise both NO and O$_2^-$ [18,19] (Fig. 1). Hence, a balanced hepatic production of NO and O$_2^-$ has to exist under physiological circumstances [19]. In the present study, we measured hepatic levels of caveolin-1 mRNA, endothelin-1 mRNA and SOD activity to find whether differences exist between healthy controls and two portal hypertensive models.

**Results**

**Western blots of eNOS, iNOS and nNOS**

The eNOS was the only NOS isoform detected in livers of all groups. The amount of eNOS protein in liver homogenates was similar in normal and PPVL rats (Fig. 2A), but was lower in CCl$_4$ cirrhotic livers (Fig. 2A), although some overlap existed with healthy controls. This is in accordance with the variable severity of the cirrhosis in this model. The iNOS protein content was below the limit of detection in livers of healthy controls and the two groups with portal hypertension (Fig. 2B). The nNOS protein was not detected in any liver homogenate (Fig. 2C). In Western blots of iNOS and nNOS but not in those of eNOS, some atypical bands of smaller proteins were observed (data not shown).

**Hepatic mRNA levels of caveolin-1 and endothelin-1**

A large variation of caveolin-1 mRNA values was present in all groups. Levels in the two portal hypertensive groups were not significantly different from healthy control values (Table 2).

Levels of endothelin-1 mRNA in the PPVL group were comparable to those of healthy control rats (Table 2), but values of CCl$_4$ cirrhotic livers were significantly and approximately 40-fold higher ($p < 0.05$ vs controls) (Table 2).

**Hepatic SOD activity**

SOD activity in liver homogenates of healthy controls was 15 (7) U/mg protein and it was 14 (3) U/mg protein in PPVL rats (Table 2). In CCl$_4$ cirrhotic livers, SOD activity was significantly reduced to 10 (3) U/mg protein ($p < 0.05$ vs normal livers) (Table 2).

**Hepatic malondialdehyde levels**

Malondialdehyde, a marker of lipid peroxidation, ranged in normal livers from 2 to 20 pmol/mg liver (median 15) and similar values were measured in PPVL rats. In CCl$_4$ cirrhotic livers, malondialdehyde levels were significantly elevated, with a median of 26 pmol/mg liver (range 6 to 130) ($p < 0.05$ vs normal livers) (Table 2).

**Discussion**

Endothelial cells are the only liver cell type that expresses eNOS [7–10] in normal and pathological conditions. In cirrhotic livers, endothelial dysfunction results in reduced eNOS activity in rat [7,9,11,12] and man [13]. A decreased bioavailability of the vasodilator NO favours vasoconstriction of liver sinusoids, especially in the presence of enhanced endothelin-1, a strong vasoconstrictor [1–3],[20–22]. NO can be produced by 3 NOS isoforms [18]. Furthermore, NO might be consumed by reactive oxygen species before it exerts vasorelaxation, as has been documented in extrahepatic vessels [17–19,23,24] (Fig. 1). In the present study, eNOS protein was the solely detected NOS isofrom in liver of normal rats and of PPVL and CCl$_4$ cirrhotic rats (Fig. 2). The eNOS is derived from endothelial cells in various vascular structures inside the liver [7,9,11]. In our search for other NOS isoforms, we could not demonstrate hepatic iNOS in any of the 3 groups (Fig. 2B), which is in agreement with other studies in normal [25,26] and CCl$_4$ cirrhotic livers [7,9,12]. Following LPS injection [27,28], hepatic iNOS could be detected (Fig. 2B). It can thus be concluded that iNOS is not contributing to portal hypertension in these two rat models. Al-
though the nNOS protein content fell below the detection limit of Western blotting in all our rats, nNOS immunostaining by others showed a dense expression around the hepatic artery and bile duct branches in the hilum of rat liver [29]. With progressive ramifications of the hepatic artery, the number of nNOS positive fibres decreases [29]. This could render nNOS undetectable (Fig. 2C) or weak [28] in parenchyma at a distance of the hilum. The issue that unknown small-size proteins sometimes stain with commercially available NOS antibodies (not shown in Figs. 2B, 2C) is discussed in detail in reference [30].

The portal vein resistance in the PPVL rat model results from the mechanical stenosis laid around the extrahepatic part of the portal vein [31]. In PPVL rats, we could not document any change in hepatic eNOS protein, endothelin-1 mRNA, caveolin-1 mRNA or SOD activity. Our findings suggest that the (atrophic) parenchyma in PPVL rats is not altering portal vein resistance importantly. In portal vein tissue below this stenosis, however, increased endothelin-1 levels have been documented and administration of endothelin-A receptor antagonists lowered the pressure in the prestenotic portal vein [32].

In the CCl₄ cirrhotic model, eNOS activity is subnormal as reported by different groups [7–9,11]. This could be due to several causes. In our CCl₄ cirrhotic rats, the amount of eNOS protein itself was subnormal (Fig. 2A), which we confirmed by immunohistochemistry [8]. Others did not find such a difference [7] but this might be related to differences in rat strains, degree of cirrhotic process or of the applied techniques, e.g., since they used an immunopre-

---

Figure 1
Proposed scheme of nitric oxide (NO) and superoxide signaling. Adapted from references [18], [24] and [34]. NO is a potent vasodilator acting through activation of soluble guanylyl cyclase in vasoactive effector cells. Superoxide is able to react with NO to form reactive nitrogen species, which could not have vasodilatory effects. Superoxide dismutase competes with NO to react with superoxide. Superoxide dismutase activity leads to breakdown of superoxide and may be regarded as a "NO sparing enzyme". Glutathione and NO may lead to possible storage of NO-derivatives.
Figure 2
Western blots of NOS isoforms. Liver homogenates of rats were used in Western blots; see Methods section. Normal rats (NL) were compared with prehepatic portal hypertensive rats, achieved by partial portal vein ligation (PPVL) and rats with carbon tetrachloride/phenobarbital induced (CCl₄) cirrhosis. (A) Western blot of eNOS, representative of eight blots. Lane 1, marked with +: Human endothelial cells were used as positive control. Lanes 2–3: two different NL livers. Lanes 4–5: two different PPVL livers. Lanes 6–7: two different CCl₄ cirrhotic livers. Prestained markers indicated the presence of 203, 120, 86, 52 kilodalton (kD) sized proteins.

(B) Western blot of iNOS, representative of two blots. Lanes 1–2: two different NL livers. Lanes 3–4: two different PPVL livers. Lanes 5–6: two different CCl₄ cirrhotic livers. Lane 7, marked with +: Liver from a rat previously treated with lipopolysaccharide was used as positive control for iNOS (see Methods). Prestained markers indicated the presence of 130 and 86 kilodalton (kD) sized proteins.

(C) Western blot of nNOS, representative of two blots. Lanes 1–2: two different NL livers. Lanes 3–4: two different PPVL livers. Lanes 5–6: two different CCl₄ cirrhotic livers. Lane 7, marked with +: Rat brain homogenate was used as positive control for nNOS (see Methods). Prestained markers indicated the presence of 130 and 86 kilodalton (kD) sized proteins.
O$_2^-$, which otherwise could rapidly convert NO into peroxynitrite and other reactive nitrogen species [17–20,23,24,35], as is given schematically in Fig 1. The observed decrease of SOD activity might allow higher intrahepatic O$_2^-$ action. In the CCl$_4$ cirrhotic rat liver, we hypothesise that enhanced intrahepatic O$_2^-$ will further reduce the already low NO and this will further amplify vasoconstrictor suppression [24]. The observation that exogenously administered superoxide doubled portal pressure in the isolated perfused liver of a normal rat [6] supports this hypothesis. The antioxidative defence enzyme SOD is present in different isoforms in all liver cell types [15]. Admittedly, we did not study SOD activity in particular liver cell types or in the vascular lumen (the latter regards the extracellular SOD isoform). SOD can easily interfere with NO and O$_2^-$ released by endothelial cells [29,36]. It is also known that activities of various SOD isoforms cannot easily be discriminated in rat liver tissue [36,37].

Presumed vasoconstrictive properties of reactive oxygen species may have consequences in chronic liver diseases with regard to the study of superoxide dismutase mimetics as treatment for portal hypertension. A recent report showed that gene transfer of the extracellular SOD isoform was beneficial in rats with endothelial dysfunction related to arterial hypertension [38].

**Conclusions**

In conclusion, we found that eNOS was the major if not the sole NOS isoform in livers of normal, PPVL and CCl$_4$ cirrhotic rats. In contrast to prehepatic portal hypertension, CCl$_4$ cirrhotic livers had decreased eNOS protein and enhanced mRNA levels of endothelin-1 but not of caveolin-1. This vasodilator/vasoconstrictor imbalance might be further aggravated by a reduced SOD activity, which could lead to enhanced superoxide-mediated inactivation of NO in liver sinusoids. The resulting low NO is unable to counteract the enhanced endothelin-1 and this results in a strong vasoconstricting effect in CCl$_4$ cirrhotic livers.

**Methods**

**Animal models**

Male Sprague-Dawley rats (Charles River Wiga, Germany) were used either as healthy controls (n = 14), for prehepatic portal hypertension (n = 6) or for CCl$_4$ induced cirrhosis (n = 11) (Table 1). In later experiments, male inbred Wistar rats (Animal House Leuven, Belgium) were used similarly as healthy controls (n = 9), for prehepatic portal hypertension (n = 5) or CCl$_4$ induced cirrhosis (n = 9) (Table 2). Prehepatic portal hypertension was achieved by partial portal vein ligation (PPVL) [31] and haemodynamic measurements were carried out 2 weeks later. CCl$_4$ induced cirrhosis was obtained by 12 weekly inhalations (Table 1) or ingestion (Table 2) of the hepatotoxin CCl$_4$, together with phenobarbital 350 mg/l in the drinking water [39]. Rats were studied 2 weeks after the last CCl$_4$ administration. Under pentobarbital anaesthesia (50 mg/kg intraperitoneally), portal venous pressure was measured in all rats, the liver was removed and 2 g of liver tissue were homogenised in 8 ml ice-cold buffer I consisting of 250 mM sucrose, 5 mM MgCl$_2$·6H$_2$O and 50 mM Tris/HCl pH 7.4. Homogenates were divided into aliquots and stored at -20°C until further processing. A small slice of liver tissue was put in guanidinium buffer on ice for 30 minutes, snap frozen in liquid nitrogen and stored at -80°C until further processing. Additionally, a small liver sample was fixed and used for haematoxylin-eosin stained paraffin-embedded sections; only those CCl$_4$ rats with micronodular cirrhosis were maintained for analysis.

**Western blotting for nNOS, iNOS and eNOS**

SDS/PAGE 7.5 % gel electrophoresis was run with diluted homogenates containing 30 µg of protein and with marker proteins (Sigma, St. Louis, USA) including a 120 kD protein, E. coli β-galactosidase. All protein concentrations were measured using the Bradford method (Bio-Rad Labs,

SOD activity enhances NO bioavailability by removing O$_2^-$, which otherwise could rapidly convert NO into peroxynitrite and other reactive nitrogen species [17–20,23,24,35], as is given schematically in Fig 1. The observed decrease of SOD activity might allow higher intrahepatic O$_2^-$ action. In the CCl$_4$ cirrhotic rat liver, we hypothesise that enhanced intrahepatic O$_2^-$ will further reduce the already low NO and this will further amplify vasoconstrictor suppression [24]. The observation that exogenously administered superoxide doubled portal pressure in the isolated perfused liver of a normal rat [6] supports this hypothesis. The antioxidative defence enzyme SOD is present in different isoforms in all liver cell types [15]. Admittedly, we did not study SOD activity in particular liver cell types or in the vascular lumen (the latter regards the extracellular SOD isoform). SOD can easily interfere with NO and O$_2^-$ released by endothelial cells [29,36]. It is also known that activities of various SOD isoforms cannot easily be discriminated in rat liver tissue [36,37].
Hemel Hempstead, UK) and with bovine serum albumin as standards. As positive controls were taken: a lysate of human aorta endothelial cells (Transduction Labs, Lexington, USA) for eNOS; a homogenate of rat brains for nNOS; and a liver of a rat given LPS 800 \( \mu \text{g/kg} \) IV (Sigma, St. Louis, USA) 6 hours before harvesting for iNOS. Samples of both portal hypertensive conditions and healthy controls were run simultaneously on the same gel. Two liver homogenate samples per liver were run. After blotting on a nitrocellulose membrane, blots were blocked overnight at 4°C. Blots were incubated for 2 hours with a mouse monoclonal antibody respectively against eNOS, nNOS or iNOS (Transduction Laboratories, Lexington, USA), dissolved at 1:1000 in buffer II (10 mM Tris-HCl pH 7.6, 0.1 M NaCl, Tween-20 at 0.1 %). Subsequently, blots were incubated with sheep anti-mouse IgG, horse-radish peroxidase-labelled (Amersham, Bucks, UK), at 1:3000 diluted in 5 % skimmed milk powder solution for one hour. After washing, detection reagents (ECL Western blotting system, Amersham, Bucks, UK) were added and blots were shortly exposed to an autoradiography film (Nen Life Science Products, Boston, USA) (Figs. 2-4) [8]. To check for adequate protein loading and blotting, all blots were stained afterwards with Ponceau S red dye (Sigma, St. Louis, USA).

**Hepatic mRNA levels of caveolin-1 and endothelin-1 with RT-PCR**

Hepatic caveolin-1 or endothelin-1 mRNA levels were assessed semi-quantitatively with RT-PCR, using serial dilutions of cDNA as a measure for the amount of specific mRNA in the different livers. Briefly, total RNA was extracted in a single step procedure [40]. The precipitated RNA was dissolved in 20-\( \mu \text{l} \) DEPC-treated water and the concentration was measured using the Ribogreen RNA quantitation kit (Molecular Probes, Eugene, USA), with ribosomal RNA as standard. One \( \mu \text{g} \) of this RNA was used for cDNA synthesis with M-MLV reverse transcriptase (GibcoBRL, Life Technologies, Merelbeke, Belgium) and random primers (Amersham Pharmacia Biotech, Little Chalfont, UK) in a volume of 20 \( \mu \text{l} \), 1 hour at 37°C. The reaction was stopped by heating in boiling water for 1 min.

The PCR primer set used for the detection of rat caveolin-1 mRNA (access number Z 46614) was:

| Table 1: Livers used for NOS Western blots. Characteristics of normal and two types of portal hypertensive rats whose livers were used for the detection of NOS isoforms by Western blot in Fig. 2. Data are expressed as mean (SD). |
|---|---|---|---|
| Normal | PPVL | CCl\(_4\) cirrhosis |
| (n = 14) | (n = 6) | (n = 11) |
| Body weight (g) | 478 (82) | 360 (27)* | 520 (70) |
| Liver weight (g) | 15.4 (3.4) | 10.3 (2.0)* | 15.8 (6.0) |
| PVP (mm Hg) | 8.1 (1.9) | 11.3 (1.7)* | 14.5 (2.7)** |

* p < 0.05 and ** p < 0.01 as compared to normal group. PPVL: partial portal vein ligation (= model of prehepatic portal hypertension). PVP: portal venous pressure. CCl\(_4\) cirrhosis: carbon tetrachloride induced cirrhosis.

| Table 2: eNOS related parameters in rat livers: caveolin-1, endothelin-1, as well as SOD total activity and malondialdehyde levels. |
|---|---|---|---|
| Normal | PPVL | CCl\(_4\) cirrhosis |
| (n = 9) | (n = 5) | (n = 9) |
| Body weight (g) | 272 (10) | 280 (13) | 355 (58)* |
| Liver weight (g) | 10.4 (0.8) | 9.7 (0.9) | 14.8 (5.6) |
| Portal venous pressure (mm Hg) | 5.0 (1.1) | 9.9 (1.5)* | 11.0 (2.9)* |
| cDNA dilutions still detecting caveolin-1 by RT-PCR | 128 [4–512] | 32 [8–256] | 384 [128–2048] |
| cDNA dilutions still detecting endothelin-1 by RT-PCR | 8 [0–64] | 13 [2–144] | 310 [16–512]* |
| SOD total activity (U/mg protein) | 15 (7) | 14 (3) | 10 (3)* |
| Malondialdehyde (pmol/mg liver) | 15 [2–20] | 8 [4–16] | 26 [6–130]* |

* p < 0.05 as compared with normal group. PPVL: partial portal vein ligation (= model of prehepatic portal hypertension). CCl\(_4\) cirrhosis: carbon tetrachloride induced cirrhosis. Livers of normal and two types of portal hypertensive rats used for the study of eNOS related parameters: caveolin-1 and endothelin-1 as well as superoxide dismutase (SOD) activity and malondialdehyde levels. For cDNA dilutions see Methods. Data are expressed as mean (SD) for normally distributed data or median [range] for not normally distributed data.
P18: 5′-CCG.GGA.ACA.GGG.CAA.CAT.CTA.CAA.GCC-3′ positions 82–108;
M28: 5′-GCC.GTC.RAA.ATT.GTG.CCC.TTC.TGG-3′ positions 251–277, resulting in a fragment of 195 bp. Note that R stands for [A,G].

The PCR primer set used for the detection of rat endothelin-1 mRNA (preproendothelin-1) (access number NM 612548) was:

P1: 5′-CAG.GTC.CAA.GCG.TTG.CTC.CG.CTC.CTC.C-3′ positions 328–355;
M2: 5′-CAC.GAC.GG.GCT.CG.TCA.ATG.TGC.TCG-3′ positions 782–811, resulting in a fragment of 483 bp.

PCR determinations were performed on a dilution series of each sample. The first sample contained cDNA equivalent to 0.25 µg total RNA; each following sample was diluted to half the concentration of the previous one. The PCR mixture contained 5 µl of cDNA solution, 6.25 pmol of each primer, 0.2 µM of each dNTP, 1 U of Taq DNA polymerase adjusted by PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 2.5 mM MgCl2 and 0.01 % gelatin) in a final volume of 50 µl. Samples were overlaid with 100 µl mineral oil. PCR conditions were identical for both primer sets: denaturing 5 min at 95°C; 45 cycles of 1 min at 95°C, 45 sec at 58°C and 45 sec at 72°C; and a final step for 5 min at 72°C, after which the samples were stored at 4°C. Samples were analysed on a 2 % agarose gel. Samples of both portal hypertensive conditions and healthy controls were separated simultaneously on the same gel. The majority of the samples were amplified and analysed at least in duplicate. Results are given as the highest dilution that gave a positive signal on the gel (Table 2).

Hepatic superoxide dismutase (SOD) activity
SOD activity in liver homogenates in buffer I was diluted 400 times with buffer I and measured with a RANSOD kit (Randox Laboratories, Crumlin, UK) according to the manufacturer’s instructions. In brief, xanthine oxidase generates O2−, which reacts with a chromogen to form a red formazan dye that is photometrically quantified. One SOD unit was defined as 55 % inhibition of dye formation. SOD activity was expressed as U/mg protein (Table 2).

Hepatic malondialdehyde levels
Determination of malondialdehyde was performed as published before [41]. Briefly, liver homogenates in buffer I were run together with 1,1,3,3-tetraethoxypropane as standard and buffer I as blanks. After the addition of phosphoric acid and thiobarbituric acid, samples were heated at 80°C for 15 min. Longer and more intense heating created too much interference of sucrose [42] (own personal observation). Ice cooled reaction products were further separated by high performance liquid chromatography-reverse phase technique [41]. The latter step is necessary to eliminate other substances that had reacted with thiobarbituric acid [43]. Results are expressed as pmol malondialdehyde/mg liver wet weight (Table 2).

Statistical analysis
Data are given as mean (SD) or as median [range] for respectively normally and non-normally distributed data. We made comparisons of the 3 groups (normal, PPVL, CCl4 cirrhosis) by one-way-analysis of variance in case of normally distributed data with equal variances. If other cases, we used analysis of variance-on-ranks, where the sum of ranks of each group was compared. When significant differences between groups means were found, the Scheffe’s posthoc test was performed to identify the groups. Significance level was always taken at α = 0.05. Statistical analyses were carried out with Sigma STAT 2.0 (Jandel Corporation, San Rafael, USA).

Ethical committee
Written approval for the present experiments was obtained from the Ethical Committees for Animal Research of the Catholic University of Leuven, Belgium, and of the University of Berne, Switzerland.

Authors’ contributions
MV and JV carried out this study together with the statistical analysis. FN participated in the design of the study. JF and JR designed and co-ordinated the study.

Acknowledgements
This study was supported by grants from the Swiss National Foundation for Scientific Research to JR (n° JR-45394-95 and 63476.00) and from the Foundation for Scientific Research, FWO-Vlaanderen (n° b.0111.98) to FN.

References
1. Wiest R and Groszmann RJ The paradox of nitric oxide in cirrhosis and portal hypertension: too much not enough. Hepatology 2002, 35:478-491
2. Bosch J and Garcia-Pagan JC Complications of cirrhosis. I Portal hypertension. J Hepatol 2000, 32(Suppl 1):141-156
3. Rockey DC Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 2000, 118:1261-1265
4. Suematsu M, Wakabayashi Y and Ishimura Y Gaseous monoxides: a new class of microvascular regulators in the liver. Cardiovasc Res 1996, 32:679-686
5. Clemens MG and Zhang JX Regulation of sinusoidal perfusion: in vivo methodology and control by endothelins. Semin Liver Dis 1999, 19:383-396
6. Kawamoto S, Tashiro S, Miyachi Y and Inoue M Changes in circulatory status and transport function of the liver induced by reactive oxygen species. Am J Physiol 1995, 268:G47-G53
7. Shah Y, Toruner M, Haddad F, Cadolina G, Papetropoulos A, Choo K, Sessa WC and Groszmann RJ Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999, 117:1222-1228
8. Van de Casteele M, Omasta A, Janssens S, Roskams T, V Desmet, Nevens F and Feveray J. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002, 51:440-445

9. Rockey DC and Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998, 114:344-351

10. Gudels A, Niki T, Helemans K, De Craemer D, Van Den Berg K, Lazzou JM, Stange G, Van De Winkel M and De Bleser P. Purification of rat hepatic stellate cells by side scatter-activated cell sorting. Hepatology 1998, 27:590-598

11. Gupta TK, Torruner M, Chung MK and Grozsmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998, 28:926-931

12. Shah V, Cao S, Hendrickson H, Yao J and Katusic ZS. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol 2001, 280:G1209-G1216

13. Sarela AI, Mihaimeed FMA, Batten JJ, Davidson BR and Mathie RT. The vascular effects of endothelin-1 plays a major role in the regulation of portal vein pressure in the rat. J Hepatol 2002, 37:99-106

14. Calvo M, Tebar F, Lopez-Iglesias C and Enrich C. Morphological and functional characterization of caveolae in rat liver hepatocytes. Hepatology 2001, 33:1259-1269

15. Housset C, Rockey DC and Bissel DM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin-1. Proc Natl Acad Sci 1993, 90:9266-9270

16. Mayer B, Pfeiffer S, Schramm A, Koessler D, Schmidt K and Brunner F. A new pathway of nitric oxide / cyclic GMP signaling involving S-nitrosoglutathione. J Biol Chem 1998, 273:3264-3270

17. Gulya TD, Day BJ and Crapo JD. Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. Lab Invest 1996, 75:617-636

18. Reichen J, Arts B, Schraffuth U, Zimmermann A, Zettner TB and Zysset T. Aminopyrine N-demethylation by rats with liver cirrhosis: Evidence for the intact cell hypothesis. A morphometric-functional study. Gastroenterology 1987, 93:719-726

19. Jentzsch AM, Bachmann H, Fürst P and Biesalski HK. Suppression of endotoxin-induced nitrotyrosine formation in vivo enhances superoxide release by the perfused liver. Am J Physiol 1994, 266:G783-G788

20. Kudus RH, Nieuwen MA, Subbotin VM, Rao AS and Gandhi CR. Functional characterization of caveolae in rat liver hepatocytes - lipocytes as a contractile target for endothelin-1. J Biol Chem 2002, 277:725-733

21. Kojima H, Sakurai S, Kuriyama S, Yoshiji H, Inazuo I, Uemura M, Nakatani Y, Yaoao J and Fukui H. Endothelin-I plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001, 34:805-811

22. Vos C and Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 2002, 91:173-178

23. Ignarro LJ, Napoli C and Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide. Circ Res 2002, 90:21-28

24. Shah V, Chen AF, Cao S, Hendrickson H, Weiler D, Smith L, Yao J and Katusic ZS. Gene transfer of recombinant endothelial nitric oxide synthase gene in vivo in vitro. J Hepatol 2000, 33:725-733

25. Kojima H, Sakurai S, Kuriyama S, Yoshiji H, Inazuo I, Uemura M, Nakatani Y, Yaoao J and Fukui H. Endothelin-I plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001, 34:805-811

26. Vos T, van Goor H, Tuyt L, de Jager-Krikken A, Leuvenink R, Kuipers F, Jansen PLM and Moshage H. Expression of inducible nitric oxide synthase in endotoxemic rat hepatocytes is dependent on the cellular glutathione status. Hepatology 1999, 29:421-426